REALISE Trial: Safety of Viaskin Peanut Patch in Children With Peanut Allergies
The REALISE trial examined the safety of epicutaneous immunotherapy with VP250 for children with peanut allergies by approximating real-world use of the agent.
Allergies
Biologic Therapies Available for Pediatric Patients With Asthma
Pediatricians should refer patients to a pediatric subspecialist to identify candidates for biologic therapy and select the appropriate medication
Dextenza Approved for Ocular Itching Associated With Allergic Conjunctivitis
The approval was based on data from three phase 3 studies that evaluated the efficacy and safety of Dextenza in patients with allergic conjunctivitis.
Many With Food Allergy Unaware of Oral Immunotherapy Option
Awareness disproportionately higher among wealthier, more highly educated respondents
Allergic Reactions to mRNA COVID-19 Vaccines Characterized
20 of 22 patients with suspected allergic reactions were women; 17 met Brighton anaphylaxis criteria
MPR Weekly Dose Podcast 83
This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Also, we look at a published report on the real-world efficacy of the COVID-19 treatment remdesivir.
FDA Approves Rx-to-OTC Switch for Astepro Allergy Nasal Spray
The FDA has approved a prescription to over-the-counter (OTC) switch for Astepro® Allergy (azelastine hydrochloride nasal spray, 0.15%).
SCIT vs SLIT for Allergic Rhinitis: Efficacy Outcomes Compared
Both treatment options were found to be effective for adults with allergic rhinitis or rhinoconjunctivitis.
Removal of EHR Warning Linked to Increase in Cephalosporin Use in Patients With Penicillin Allergy
After removal of the warning, cephalosporin use increased from 17.9% to 27.0% at the intervention site.
MPR Weekly Dose Podcast 76
In this week’s pod, the FDA review the Emergency Use Authorization for bamlanivimab; Issues are identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID therapy; A novel contraceptive is approved; And Ragwitek has its approval expanded.
